RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma

BACKGROUND: Neoadjuvant chemotherapy – often using docetaxel in various combinatorial regimens – is a standard treatment choice for advanced oesophageal squamous cell carcinoma (ESCC) in Japan. However, no useful markers exist that predict docetaxel’s effects on ESCC. Ribophorin II (RPN2) silencing,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kurashige, J, Watanabe, M, Iwatsuki, M, Kinoshita, K, Saito, S, Nagai, Y, Ishimoto, T, Baba, Y, Mimori, K, Baba, H
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2012
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494434/
https://ncbi.nlm.nih.gov/pubmed/22955852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.396
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller